These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 36559218)
1. PET Imaging of the Neurotensin Targeting Peptide NOTA-NT-20.3 Using Cobalt-55, Copper-64 and Gallium-68. Houson HA; Tekin V; Lin W; Aluicio-Sarduy E; Engle JW; Lapi SE Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559218 [TBL] [Abstract][Full Text] [Related]
2. Synthesis of Fonseca Cabrera GO; Ma X; Lin W; Zhang T; Zhao W; Pan L; Li X; Barnhart TE; Aluicio-Sarduy E; Deng H; Wu X; Rakesh KP; Li Z; Engle JW; Wu Z J Nucl Med; 2024 Aug; 65(8):1250-1256. PubMed ID: 38871388 [TBL] [Abstract][Full Text] [Related]
3. Theranostic cobalt-55/58m for neurotensin receptor-mediated radiotherapy in vivo: A pilot study with dosimetry. Lin W; Aluicio-Sarduy E; Houson HA; Barnhart TE; Tekin V; Jeffery JJ; Weichmann AM; Barrett KE; Lapi SE; Engle JW Nucl Med Biol; 2023; 118-119():108329. PubMed ID: 36805869 [TBL] [Abstract][Full Text] [Related]
4. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors. Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976 [TBL] [Abstract][Full Text] [Related]
5. Chelator boosted tumor-retention and pharmacokinetic properties: development of Zhang T; Ma X; Xu M; Cai J; Cai J; Cao Y; Zhang Z; Ji X; He J; Cabrera GOF; Wu X; Zhao W; Wu Z; Xie J; Li Z Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3322-3333. PubMed ID: 38771516 [TBL] [Abstract][Full Text] [Related]
6. Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423 [TBL] [Abstract][Full Text] [Related]
8. Preclinical PET Imaging of NTSR-1-Positive Tumors with Li D; Minnix M; Allen R; Bading J; Chea J; Wong P; Bowles N; Poku E; Shively JE Cancer Biother Radiopharm; 2021 Oct; 36(8):651-661. PubMed ID: 32822229 [No Abstract] [Full Text] [Related]
9. Imaging Neurotensin Receptor in Prostate Cancer With Deng H; Wang H; Zhang H; Wang M; Giglio B; Ma X; Jiang G; Yuan H; Wu Z; Li Z Mol Imaging; 2017; 16():1536012117711369. PubMed ID: 28849698 [TBL] [Abstract][Full Text] [Related]
10. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent. Brand C; Longo VA; Groaning M; Weber WA; Reiner T Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631 [TBL] [Abstract][Full Text] [Related]
11. PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule. Su X; Cheng K; Liu Y; Hu X; Meng S; Cheng Z Amino Acids; 2015 Jul; 47(7):1409-19. PubMed ID: 25854877 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of peptide-based imaging agents [ Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995 [TBL] [Abstract][Full Text] [Related]
13. Preparation and Evaluation of [ Dam JH; Langkjær N; Baun C; Olsen BB; Nielsen AY; Thisgaard H Molecules; 2022 Oct; 27(20):. PubMed ID: 36296411 [TBL] [Abstract][Full Text] [Related]
14. Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate. Nedrow JR; White AG; Modi J; Nguyen K; Chang AJ; Anderson CJ Mol Imaging; 2014; 13():. PubMed ID: 25060207 [TBL] [Abstract][Full Text] [Related]
15. Targeting of MMP2 activity in malignant tumors with a 68Ga-labeled gelatinase inhibitor cyclic peptide. Liu Q; Pan D; Cheng C; Zhang A; Ma C; Wang L; Zhang D; Liu H; Jiang H; Wang T; Xu Y; Yang R; Chen F; Yang M; Zuo C Nucl Med Biol; 2015 Dec; 42(12):939-44. PubMed ID: 26344861 [TBL] [Abstract][Full Text] [Related]
16. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging. Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125 [TBL] [Abstract][Full Text] [Related]
17. Novel radiolabeled peptides for breast and prostate tumor PET imaging: (64)Cu/and (68)Ga/NOTA-PEG-[D-Tyr(6),βAla(11),Thi(13),Nle(14)]BBN(6-14). Fournier P; Dumulon-Perreault V; Ait-Mohand S; Tremblay S; Bénard F; Lecomte R; Guérin B Bioconjug Chem; 2012 Aug; 23(8):1687-93. PubMed ID: 22770480 [TBL] [Abstract][Full Text] [Related]
18. In Vivo Evaluation of a Bombesin Analogue Labeled with Ga-68 and Co-55/57. Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H Mol Imaging Biol; 2016 Jun; 18(3):368-76. PubMed ID: 26561028 [TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. Baun C; Mitran B; Rinne SS; Dam JH; Olsen BB; Tolmachev V; Orlova A; Thisgaard H Molecules; 2020 Dec; 25(24):. PubMed ID: 33352838 [TBL] [Abstract][Full Text] [Related]
20. Targeting Phosphatidylserine with a Perreault A; Richter S; Bergman C; Wuest M; Wuest F Mol Pharm; 2016 Oct; 13(10):3564-3577. PubMed ID: 27608290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]